Results 61 to 70 of about 25,691 (210)

Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells. [PDF]

PLoS ONE, 2016
Current treatment of retinoblastoma involves using the maximum dose of chemotherapy that induces tumor control and is tolerated by patients. The impact of dose and schedule on the cytotoxicity of chemotherapy has not been studied.
Ursula Winter, Hebe A Mena, Soledad Negrotto, Eloisa Arana, Guillem Pascual-Pasto, Viviana Laurent, Mariona Suñol, Guillermo L Chantada, Angel M Carcaboso, Paula Schaiquevich   +9 more
doaj   +1 more source

Lactone Stabilized by Crosslinked Cyclodextrin Metal-Organic Frameworks to Improve Local Bioavailability of Topotecan in Lung Cancer

Pharmaceutics, 2022
The protection of unstable anticancer molecules and their delivery to lesions are challenging issues in cancer treatment. Topotecan (TPT), a classic cytotoxic drug, is widely used for treating refractory lung cancer.
Ting Xiong, Tao Guo, Yaping He, Zeying Cao, Huipeng Xu, Wenting Wu, Li Wu, Weifeng Zhu, Jiwen Zhang   +8 more
doaj   +1 more source

E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer. [PDF]

, 2013
PURPOSE: Sequence-dependent improved efficacy of topoisomerase I followed by topoisomerase 2 inhibitors was assessed in a randomized phase II study in extensive-stage small-cell lung cancer (SCLC).
Aisner, Joseph, Axelrod, MD, Rita S., Dahlberg, Suzanne E., Gounder, Murugesan, Owonikoko, Taofeek K., Ramalingam, Suresh S., Rausch, Paul Gregory, Rubin, Eric H., Schiller, Joan H., Wang, Xin Victoria   +9 more
core   +2 more sources

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman, Madeleine King, Rajen Mody, Sara‐Jane Onyeama, Araz Marachelian, Thomas Cash, Sara M. Federico, Meaghan Granger, Ami V. Desai, Suzanne Shusterman, Jennifer H. Foster, Elizabeth Sokol, Chelsee Greer, Keri Streby, Holly J. Meany, Kieuhoa T. Vo, Margaret E. Macy, Rochelle Bagatell   +17 more
wiley   +1 more source

A simulated trial with reinforcement learning for the efficacy of Irinotecan and Ifosfamide versus Topotecan in relapsed, extensive stage small cell lung cancer

BMC Cancer
Objectives Synthetic data may proxy clinical data. At the absence of direct clinical data, this study aimed to compare Irinotecan and Ifosfamide (II) with Topotecan in synthetic, recurrent small cell lung cancer (SCLC) patients within a simulated ...
Hakan Şat Bozcuk, Mehmet Artaç
doaj   +1 more source

Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells.

PLoS ONE, 2013
Gliomas, the most malignant form of brain tumors, contain a small subpopulation of glioma stem cells (GSCs) that are implicated in therapeutic resistance and tumor recurrence.
Feng-Lei Zhang, Ping Wang, Yun-Hui Liu, Li-Bo Liu, Xiao-Bai Liu, Zhen Li, Yi-Xue Xue   +6 more
doaj   +1 more source

Pharmacologic topoisomerase-I inhibition causes DNA damage and mortality in activated CD4+ T cells

Genetics & Applications, 2018
Topoisomerase-I is required for DNA replication. It acts by preventing torsional stress caused by DNA winding during replication fork progression.  Topoisomerase-I inhibitors are widely used in many cancer therapies, in light of their anti-proliferative ...
Mia Stanić, Iart Luca Shytaj, Marina Lusic   +2 more
doaj   +3 more sources

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson, Menna Shamma, Upeka Senanayake, Shaimaa Sahmoud, Kathleen Duffin, Victoria Howard, David King, Ayesha Fathani, Blanche Lumb, Andrei Pobischan, Irum Latif Memon, Monzir Ahmed, Rhian Thomas, Gerard Millen, Yasmeen Alomari, Sucheta Vaidya, Lynley V. Marshall, Sally L. George, Ramya Ramanujachar, Juliet Gray, Paola Angelini   +20 more
wiley   +1 more source

Molecular signatures of xenograft colorectal cancer in mice treated with topotecan: A mass spectrometry-based study

Toxicology Reports
Background: Colorectal cancer (CRC) is one of the most common cancers worldwide, yet it continues to have a low survival rate, largely due to the lack of effective treatments.
Yousra A. Hagyousif, Ruba A. Zenati, Nelson C. Soares, Hamza M. Al-Hroub, Farman Matloob Khan, Rizwan Qaisar, Rifat Hamoudi, Raafat El-Awady, Ahmad Y. Abuhelwa, Wafaa Ramadan, Waseem El-Huneidi, Eman Abu-Gharbieh, Karem H. Alzoubi, Yasser Bustanji, Mohammad H. Semreen   +14 more
doaj   +1 more source

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. [PDF]

, 2013
The widespread use of trastuzumab in the past decade has led to a significant and measureable improvement in the survival of patients with human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer, and in many ways has redefined the ...
Chien, A Jo, Rugo, Hope S
core   +1 more source